One-Year Visual Outcomes After Bilateral Implantation Of Trifocal Iols Made From A New Hydrophobic Acrylic Material
Published 2024 - 42nd Congress of the ESCRS
Reference: PP20.18 | Type: Free paper | DOI: 10.82333/7frj-8974
Authors: Kenichiro Yamazaki* 1 , Junko Yoneyama 1 , Ryuta Kimoto 1 , Takahiko Hayashi 2 , Tatsuya Mimura 3
1Omiya Nanasato Eye Institute,Saitama,Japan, 2Nihon University,Tokyo,Japan, 3Teikyo University,Tokyo,Japan
Purpose
Clareon®︎ (Alcon) is a next-generation acrylic material following AcrySof®︎ designed to improve transparency and suppress the occurrence of glistening. Clareon®︎ PanOptix®︎ is a trifocal intraocular lens made from Clareon®︎, and has the same optical design as AcrySof®︎ IQ PanOptix®︎. Aim of this study is to evaluate 1-year visual outcomes after bilateral implantation of non-toric or toric Clareon®︎ PanOptix®︎.
Setting
Omiya Nanasato Eye Institute, Saitama, Japan
Methods
A prospective study enrolling 156 eyes (78 patients; age 68 ± 8.0 year) undergoing femtosecond laser-assisted cataract surgery with bilateral implantation of CNWTT0 or CNWTT3-6 was performed. Types of toric IOLs were selected using Barrett Toric Calculator. Manifest refraction, uncorrected distance visual acuity (UDVA) at 5 m, corrected distance visual acuity (CDVA), distance-corrected intermediate visual acuity (DCIVA) at 80 cm and 60 cm, uncorrected near visual acuity (UNVA) at 40 cm, corrected near visual acuity (CNVA) at 40 cm, defocus curves and dysphotopsia were evaluated up to 12 months postoperatively.
Results
The implanted IOL models were CNWTT0 (80 eyes), T3 (55 eyes), T4 (19 eyes), T5 (13 eyes), T6 (9 eyes). At 12 months, the mean manifest refractive sphere and cylinder were -0.14 D and -0.33 D. UDVA and CDVA were 0.05 ± 0.14 and -0.09 ± 0.08 logMAR, DCIVA at 80 cm and 60 cm were 0.09 ± 0.08 and 0.11 ± 0.10 logMAR, UNVA and CNVA were 0.11 ± 0.11 and 0.06 ± 0.09 logMAR, respectively. Contrast sensitivity levels under photopic condition were 1.70 ± 0.19, 1.88 ± 0.21, 1.52 ± 0.23, 1.06 ± 0.22 (log units) at 3, 6, 12, 18 cycles per degree, respectively. Spectacle independence rate was 94.9%. No patients reported severe dysphotopsia which prevent daily activities including night car driving. Glistening was not observed in 12 months period.
Conclusions
The Clareon®︎ PanOptix®︎ provides high visual performance in all distance and spectacle independence with a low rate dysphotopsia profile in the long term. Clareon®︎ PanOptix®︎, to date, offers visual performance comparable to AcrySof®︎ IQ PanOptix®︎; however, additional follow-up is necessary to evaluate glistening.